Logo

VIVS

VivoSim Labs, Inc.

VIVS

VivoSim Labs, Inc. • NASDAQ
$2.24 ▲ 2.28% (+0.05)
Market Cap $5.84 M
52w High $21.96
52w Low $1.41
Dividend Yield 0%
P/E 4.39
Volume 17.57K
Outstanding Shares 2.61M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2026 $28K ▼ $2.663M ▼ $-2.545M ▲ -9.089K% ▼ $-0.98 ▲ $-2.484M ▲
Q1-2026 $37K ▼ $2.952M ▼ $-2.843M ▼ -7.684K% ▼ $-1.94 ▼ $-2.778M ▼
Q4-2025 $51K ▲ $3.205M ▼ $6.852M ▲ 13.435K% ▲ $4.68 ▲ $6.918M ▲
Q3-2025 $24K ▼ $3.49M ▲ $-3.447M ▼ -14.363K% ▼ $-2.28 ▼ $-3.375M ▼
Q2-2025 $30K $2.637M $-2.549M -8.497K% $-1.68 $-2.54M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2026 $6.677M ▼ $9.686M ▼ $2.621M ▲ $7.065M ▼
Q1-2026 $9.055M ▼ $11.978M ▼ $2.44M ▼ $9.538M ▼
Q4-2025 $11.312M ▲ $14.65M ▲ $4.158M ▲ $10.492M ▲
Q3-2025 $1.161M ▼ $3.844M ▼ $3.48M ▲ $364K ▼
Q2-2025 $3.174M $6.754M $3.074M $3.68M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-2.843M ▼ $-3.94M ▼ $0 ▼ $1.683M ▼ $-2.257M ▼ $-3.94M ▼
Q4-2025 $6.852M ▲ $-2.035M ▼ $9.001M ▲ $3.185M ▲ $10.151M ▲ $-2.035M ▼
Q3-2025 $-3.447M ▼ $-1.801M ▲ $4K ▲ $-216K ▲ $-2.013M ▲ $-1.801M ▲
Q2-2025 $-2.549M ▲ $-2.642M ▲ $0 ▼ $-371K ▼ $-3.013M ▼ $-2.655M ▲
Q1-2025 $-3.344M $-2.983M $20K $6.249M $3.286M $-2.983M

Five-Year Company Overview

Income Statement

Income Statement VivoSim Labs is essentially still a pre‑revenue biotech story. Over the past several years, it has not generated meaningful sales, and results are driven almost entirely by research, development, and overhead costs. Those costs translate into recurring net losses each year. The loss levels appear modest in absolute dollars but material relative to the company’s small size, reflecting a business that is still investing in its platform well ahead of commercial scale. With no operating revenue to offset expenses, progress on partnerships, service contracts, and any milestone payments will matter far more than historical earnings for now.

Balance Sheet

Balance Sheet The balance sheet is very light and simple. Assets are small and largely made up of cash, with little in the way of physical infrastructure or long‑lived equipment. The company carries no debt, which reduces financial pressure from interest or scheduled repayments. However, the equity base is also very thin, leaving only a modest cushion to absorb ongoing losses. This combination—cash but very little net worth—highlights both a low leverage profile and a dependence on external capital raises or upfront partnership funding to sustain operations over time.

Cash Flow

Cash Flow Cash flow reflects a typical early‑stage biotech pattern: steady cash outflows from operations and no offsetting inflows from a commercial business. Operating and free cash flow have been consistently negative, while capital spending has been minimal, indicating that most cash use is for people, research, and running the lab rather than for heavy equipment. This means the company is “burning cash” at a relatively stable but ongoing rate. Without recurring revenue, the business will likely continue to rely on new equity, grants, or collaboration payments to fund its work, and careful cash management will remain critical.

Competitive Edge

Competitive Edge VivoSim occupies a differentiated niche at the intersection of 3D bioprinting, advanced tissue modeling, and AI‑driven prediction. Its NAMkind platform and proprietary bioprinting processes give it a technology and data advantage in human‑relevant preclinical testing, especially for liver and intestinal models. Regulatory support for alternatives to animal testing, combined with the company’s early‑mover experience and specialized know‑how, helps form a budding competitive moat. Validation through a partnership with a large pharmaceutical company is a meaningful signal of credibility. Still, VivoSim is small and operates in a field that is attracting well‑funded competitors and large incumbents, so scaling commercial adoption and maintaining a lead in model accuracy and data will be ongoing challenges.

Innovation and R&D

Innovation and R&D The company is highly innovation‑driven. Its core value lies in its NAMkind platform, which combines 3D bioprinted human tissues with AI to predict drug safety and efficacy more accurately than traditional models. This is both a technology and data play: each study generates proprietary datasets that can strengthen its algorithms over time. On top of services, VivoSim is building its own drug pipeline, using its models to select and refine candidates such as an FXR‑focused program for inflammatory bowel disease, plus at least one additional, undisclosed target. Expanding to more organ systems and more complex tissue models could broaden its addressable market. As with all biotech R&D, timelines are long and outcomes uncertain, so the value of this innovation will depend on reproducible results, regulatory acceptance, and successful translation into clinical and commercial milestones.

Summary

Overall, VivoSim Labs is a science‑heavy, early‑stage biotech with minimal current revenue and ongoing losses, supported by a very lean balance sheet and a specialized technology platform. Its story is far more about future potential than about present financial strength. The key positives are a differentiated 3D bioprinting and AI platform, strong alignment with regulatory trends away from animal testing, and external validation through at least one notable pharmaceutical partnership. The main risks center on funding needs, the absence of a scaled commercial business today, execution in converting technology into repeatable revenue, and the inherent uncertainty of drug development. Going forward, the most important indicators to watch are: adoption of its NAMkind services, additional strategic collaborations, progress of its internal drug candidates, and how effectively it manages cash while advancing R&D.